Differential iron requirements for osteoblast and adipocyte differentiation by Edwards, D.F. et al.
ORIGINAL ARTICLE
Differential Iron Requirements for Osteoblast
and Adipocyte Differentiation
Daniel F. Edwards III,1 Christopher J. Miller,1 Arelis Quintana-Martinez,1 Christian S. Wright,2
Matthew Prideaux,3 Gerald J. Atkins,4 William R. Thompson,2 and Erica L. Clinkenbeard1
1Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis, IN, USA
2Department of Physical Therapy, School of Health & Human Sciences, Indiana University, Indianapolis, IN, USA
3Indiana Center for Musculoskeletal Health, Indiana University, Indianapolis, IN, USA
4Centre for Orthopaedic & Trauma Research, University of Adelaide, Adelaide, South Australia, Australia
ABSTRACT
Bone marrow mesenchymal progenitor cells are precursors for various cell types including osteoblasts, adipocytes, and chondro-
cytes. The external environment and signals act to direct the pathway of differentiation. Importantly, situations such as aging and
chronic kidney disease display alterations in the balance of osteoblast and adipocyte differentiation, adversely affecting bone integ-
rity. Iron deficiency, which can often occur during aging and chronic kidney disease, is associated with reduced bone density. The
purpose of this study was to assess the effects of iron deficiency on the capacity of progenitor cell differentiation pathways. Mouse
and human progenitor cells, differentiated under standard osteoblast and adipocyte protocols in the presence of the iron chelator
deferoxamine (DFO), were used. Under osteogenic conditions, 5μMDFO significantly impaired expression of critical osteoblast genes,
including osteocalcin, type 1 collagen, and dentin matrix protein 1. This led to a reduction in alkaline phosphatase activity and
impaired mineralization. Despite prolonged exposure to chronic iron deficiency, cells retained viability as well as normal hypoxic
responses with significant increases in transferrin receptor and protein accumulation of hypoxia inducible factor 1α. Similar concen-
trations of DFO were used when cells were maintained in adipogenic conditions. In contrast to osteoblast differentiation, DFO mod-
estly suppressed adipocyte gene expression of peroxisome-proliferating activated receptor gamma, lipoprotein lipase, and
adiponectin at earlier time points with normalization at later stages. Lipid accumulation was also similar in all conditions. These data
suggest the critical importance of iron in osteoblast differentiation, and as long as the external stimuli are present, iron deficiency
does not impede adipogenesis. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society
for Bone and Mineral Research.
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Introduction
I ron is an essential trace element used in many biological pro-cesses. The most critical of these applications is incorporation
within heme for generation of hemoglobin in red blood cells
and the transport of oxygen.(1) Iron functions in other cellular
capacities, including serving as a cofactor for numerous enzy-
matic reactions. Thus, iron deficiency exhibits a wide range of det-
rimental effects inmultiple tissues and biological procedures. Iron
deficiency is one of the most widespread mineral deficiencies
worldwide,(2) primarily caused by insufficient dietary uptake,(3)
inflammation-mediated functional iron deficiency,(4,5) or blood
loss.(6) Studies in both rodents and humans show alterations in
bone homeostasis during chronic iron deficiency. BMD is reduced
with chronic low-iron–diet feeding in rats.(7-9) In humans, chronic
iron deficiency anemia is associated with increased fracture risk,
independent of other risk factors, such as hypertension or
BMI.(10) With aging, the incidence of iron-deficiency anemia
increases,(11) and dietary iron was shown to ifluence postmeno-
pausal women bone density parameters.(12,13)
Bone mineralization is mediated by osteoblasts that are
derived frommesenchymal stromal cells (MSCs) within the bone
marrow. MSCs undergo highly coordinated differentiation pro-
gramming to generate osteogenic cells capable of producing
and secreting osteoid matrix for mineralization. The effects of
iron deficiency using the iron chelator deferoxamine (DFO) on
osteoblasts have provided controversial results. Initial studies
used DFO as an hypoxia mimetic to target hypoxia-inducible
factor (HIF) stabilization, as iron is a cofactor of prolyl-
hydroxylase domain containing (PHD) proteins that signal HIF
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degradation.(14) Activation of HIF1α in low-oxygen tension-
culturing conditions or promotion of HIF1α accumulation
through blockade of the degradation pathway, enhanced osteo-
blast differentiation both in vitro(15–18) and in vivo.(19–21) Alterna-
tively, iron overload is associated with impaired osteoblast
activity.(22,23) In some postmenopausal osteoporosis studies, iron
chelation is found to have a beneficial effect as this prevents iron
overload(24,25) and potentially cell death.(26)
MSCs are capable of differentiation toward several cell types,
including the osteogenic, chondrogenic, and adipogenic line-
ages.(27,28) Aging, in both humans and mice, exhibits an accumu-
lation of bone marrow adipocytes,(29,30) which is negatively
associated with bone strength.(31) Anemia frequently occurs dur-
ing aging and in chronic diseases, yet the mechanism of dis-
rupted bone homeostasis during iron deficiency remains
unclear. In this study, we use amouse progenitor cell line and pri-
mary humanMSCs (hMSCs) to evaluate osteoblast and adipocyte
differentiation in the presence of DFO to mimic chronic iron defi-
ciency. We found that osteogenic differentiation is significantly
disrupted with chronic DFO treatment despite upregulation of
HIF1α and is not caused by increased cell death. Interestingly,
similar DFO concentrations in adipogenic conditions failed
to impede adipocyte differentiation. Therefore, osteoblasts




MPC2 cells(32) were grown in α modified essential medium
(Hyclone) supplemented with 10% FBS (Lot nos. K19151 and
B18021; Atlanta Biologicals), 1% L-glutamine (Hyclone), and 1%
penicillin/streptomycin (Hyclone) andmaintained at the prolifer-
ative temperature (33C) with 5% CO2. To induce differentiation,
MPC2 cells were seeded at 1.5  105 cells/mL in growth media
and grown to 80% confluency. For osteogenic differentiation,
growth medium was supplemented with 50μg/mL L-ascorbic
acid (Fisher Scientific) and 4mM β-glycerophosphate (Fisher Sci-
entific), after which cells were placed at 37C. Adipogenic differ-
entiation was induced with growth media supplemented with
0.1μM dexamethasone (Sigma), 5μg/mL insulin (Sigma), and 50
μM indomethacin (Sigma) and similarly transferred to 37C.
Deferoxamine mesylate (Sigma) was dissolved in water, then fil-
ter sterilized and added to the media at the indicated concentra-
tions at the initiation of differentiation (water used as vehicle
control). Media was changed every 2 to 3 days and contained
all of the supplementations described above; cells were har-
vested at the indicated time points. Experiments included differ-
ent batches of thawed cells and passages 6 to 20.
Human progenitor cells
Human MSCs from two healthy donors (Lonza; 28- and 31-year-
old men) were grown in Mesencult (Lonza) media according to
the manufacturer’s protocol at 37C with 5% CO2 using cell pas-
sages 3 to 7 from different batches of thawed cells. To induce
osteoblast differentiation, cells were seeded at 1.5  105 cells/
mL and grown to confluency, where the growth medium was
replaced with osteogenic media: DMEM supplemented with
10% FBS, 1% penicillin/streptomycin, 50μM ascorbic acid,
10mM β-glycerophosphate, and 10nM dexamethasone. For adi-
pogenic differentiation, growth media was replaced with
adipogenic media: DMEM supplemented with 10% FBS, 1% pen-
icillin/streptomycin, 0.1μM dexamethasone, 0.5mM 3-isobutyl-
1-methylxanthine (IBMX; Sigma), 0.2mM indomethacin, and
10μg/mL insulin. DFO was added to the media at the indicated
concentrations at the initiation of differentiation. Media were
changed every 2 to 3 days and cells were harvested at the indi-
cated time points.
Iron supplementation
MPC2 cells and hMSCs were seeded in 12-well plates and
allowed to come to 80% confluency in appropriate standard
growth media and conditions. The media for each cell type was
then changed to undergo osteogenic differentiation as
described above. A subset of wells was additionally supplemen-
ted with 5μMDFO. Holo-transferrin (Sigma), the iron-bound form
of transferrin, was added to the control and DFO treated wells at
two concentrations: 0.1 and 1 mg/mL. Apo-transferrin, with no
iron bound, was added to normalize transferrin protein levels
so that the final total transferrin concentration remained consis-
tent at 1.2 mg/mL across the treatments. Vehicle control was
pure water. Media was changed every 2 to 3 days and RNA isola-
tion and staining took place at the indicated time points.
Osteoblast staining
Between 21 and 28 days of osteoblast differentiation, media was
removed and washed with PBS. Evaluation of mineralization
occurred with Alizarin Red (Sigma). Briefly, cells were fixed in cold
70% ethanol and stained with 2% Alizarin Red. After imaging,
Alizarin Red stain was eluted with 100mM cetylpyridinium chlo-
ride and measured in a spectrophotometer at 405 nm to deter-
mine terminal mineralization. To measure functional alkaline
phosphatase activity, replicate wells in a 12-well plate were lysed
(Cell Signaling) at the indicated time points, and the supernatant
assayed with an alkaline phosphatase kit (Pointe Scientific)
according to the manufacturer’s protocol. Measurements at
one-min intervals for a total of fivemeasurements were collected
on the Epoch one-plate reader (BioTek) and normalized to total
protein levels quantified with the Bradford Coomassie assay
(Pierce).
Adipocyte staining
At 7, 14, and 21 days after adipogenic differentiation, media
were removed from the plates and cells washed in PBS. The cells
were then stained with 70% Oil Red O (Sigma) in propylene gly-
col (Fisher Scientific). Wells were rinsed until any unbound stain
no longer remained and were allowed to dry. Images were col-
lected on a Leica inverted scope using the 4 objective. Oil
Red O staining then was eluted from triplicate wells in isopropa-
nol (Fisher Scientific) and read on the Epoch One spectropho-
tometer plate reader at 490 nm for semiquantitative analysis of
Oil Red O content.
Cell death assay
MPC2 cells and hMSCs were plated on sterile glass chamber
slides (Fisher Scientific) at 1.5  105 cells/mL. Once the cells
reached 70% confluency themediumwas changed to the appro-
priate corresponding osteogenic media and increasing concen-
trations of DFO. At the indicated time points, the media was
removed from the cells and the wells were washed with PBS.
The slides were fixed in 10% buffered formalin and underwent
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fluorescent terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL; Sigma) according to the manufacturer’s instruc-
tions. DNaseI (Thomas Scientific) treatment was used as a posi-
tive control for staining as suggested by the manufacturer
(Supplementary information Fig. S1). Coverslips were mounted
with ProLong Gold containing 4,6-diamidino-2-phenylindole
(DAPI; Life Technologies) and four images per chamber were
captured using a Leica fluorescent microscope. ImageJ software
(NIH; https://imagej.nih.gov/ij/) was used to quantify DAPI-
positive and TUNEL-positive cells. Each condition was conducted
in two different chambers and the experiment was performed at
least three times.
Western blot
Protein was isolated from each cell type at the indicated time
points from 6-well plates in 1 cell lysis buffer (Cell Signaling)
containing the protease inhibitor AEBSF (Sigma). Lysate concen-
trations were quantified using the Bradford Coomassie color-
metric assay (Pierce), and supernatants were run on SDS-page
gels (Bio-Rad) and transferred to polyvinylidene fluoride mem-
branes (Bio-Rad). Blots were probed using primary antibodies
for HIF1α (1:500; Novus Biologicals) and normalized to horserad-
ish peroxidase tagged β-actin (1:15,000; Sigma).
RNA analysis
RNAwas isolated directly from the cells in culture using the Pure-
Link RNA extraction kit (Invitrogen) according to the manufac-
turer’s instructions. A total of 50-ng RNA was then analyzed in
the TaqMAn OneStep RNA to Ct kit (Life Technologies). We used
TaqMan primer/probe mix (ABI) for the following genes for
mouse/human: Runx2/RUNX2, SP7, Bglap/BGLAP, Col1a1/COL1A1,
Dmp1/DMP1, Pparɣ/PPARɣ, Adipoq/ADIPOQ, and Lpl/LPL, which
Fig. 1. MPC2 osteoblast differentiation inhibition with deferoxamine (DFO). (A) Sp7, (B) Col1a1, (C) Bglap, and (D) Dmp1 mRNA measured from undiffer-
entiated cells or those differentiated in osteogenic media with 1, 2.5 or 5μMDFO for 7 and 14 days. (E) Alizarin Red staining on MPC2 cells after 21 days of
osteogenic differentiated cells (*p < 0.05, **p < 0.02, and ***p < 0.001 as determined by matched two-way analysis of variance [ANOVA]). (F) Alkaline
phosphatase activity in osteogenic differentiated MPC2 cells at day 14. (G) Alizarin Red semiquantification after terminal osteoblast differentiation at
day 21 (*p < 0.05, **p < 0.01, and ***p < 0.001 as determined by one-way ANOVA).
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were run on a Quant Studio 3 Real-Time PCR instrument (Life
Technologies). MPC2 genes were normalized to either hypoxan-
thine guanine phosphoribosyl transferase (Hprt) or VIC-labeled
primer limited Actb; hMSCs were normalized to VIC-labeled-
primer limited ACTB and calculated using the 2-Δ/ΔCt calculation
method using day 1 controls as baseline. Primer/probe informa-
tion is available upon request.
Statistical analysis
Data are presented as individual data points from two to three
replicates along with mean  SD. One-way or matched two-
way ANOVA was used when Gaussian distribution was normal
for statistical analysis between doses/time. If significant values
were obtained, Tukey’s post hoc multiple comparisons were per-
formed. If the Gaussian distribution failed with the D’Agostino-
Pearson test, a nonparametric one-way ANOVA Kruskal-Wallis
test was conducted. Threshold cutoff for a significant p value
was designated at p ≤ 0.05 (GraphPad Prism).
Results
Osteoblast differentiation requires physiologically
normal iron
Under osteogenic conditions, MPC2 cells exhibited expression of
various osteoblast genes including osterix (Sp7), type 1 collagen
(Col1a1), osteocalcin (Bglap), and dentin matrix protein 1 (Dmp1;
Fig. 1A–D). The iron chelator deferoxamine (DFO) was introduced
at increasing concentrations (1–5μM) at the onset of differentia-
tion to mimic chronic iron deficiency. After 7 days of differentia-
tion with 5μM DFO, a modest yet significant reduction in Col1a1
mRNA was observed. After 14 days of differentiation, DFO signif-
icantly reduced BglapmRNA levels in a dose-dependent manner.
Both Col1a1 and Dmp1 showed a significant reduction in the
presence of 5μMDFO, whereas Sp7mRNA levels remained stable
across all conditions (Fig. 1A–D). These gene-expression changes
correlated with a reduction in alkaline phosphatase activity and
Alizarin Red-stained mineralized nodules in the 5μM DFO-
treated cells versus control (Fig. 1E-G).
Fig. 2. MPC2 cells treated with deferoxamine (DFO) retain iron-adaptive responses and cell viability, as well as exhibit normal differentiation with phys-
iological iron. (A) Tfrc mRNA measured from MPC2 cells undergoing osteogenic differentiation for 7 and 14 days with increasing DFO concentrations
(**p < 0.01 and ****p < 0.0001). (B) Representative 10microscopic images for MPC2 cells stained for TUNEL (green) and 4,6-diamidino-2-phenylindole
(blue) after 7 and 14 days of osteogenic differentiation (10; scale bar= 200μM). (C) Quantitation of % dead cells after 1, 3, 7, and 14 days of osteogenic
differentiation with all doses of DFO (Kruskal-Wallis test performed at each time point). (D) MPC2 cells in osteoblast differentiation was supplementedwith
combinations of 5μMDFOwith low concentration or high concentration of iron bound holo-transferrin and stained for Alizarin Red after 21 days (E), which
were then quantified (p < 0.05 based on one-way analysis of variance [ANOVA]). (F) Tfrc, (G) Bglap, and (H) Dmp1mRNA expression levels were measured
after 7 and 14 days in these conditions (*p < 0.05, **p < 0.01, and ****p < 0.0001 based on matched two-way ANOVA).
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Low iron and hypoxic states are known to increase transcrip-
tion of transferrin receptor (Tfrc) mRNA.(33) Compared with con-
trol cells, Tfrc mRNA showed a DFO-dependent induction at
both day 7 and day 14, suggesting that cells were attempting
to adapt to the reduced iron conditions (Fig. 2A). Substantial iron
deficiency is also known to induce apoptosis.(34) To determine if
blunted osteoblast differentiation was a result of cell death,
MPC2 cells were cultured on glass slides and underwent TUNEL
staining to quantify the level of apoptosis induced by DFO
(Fig. 2B). After 24 hours of adding osteogenic differentiation
media with or without DFO, there was no increase in TUNEL-
positive apoptotic cells in the DFO-treated wells. At later time
points, a modest increase in TUNEL-positive cells was observed
for the MPC2 osteogenic cells treated with 5μM DFO; however,
it did not reach statistical significance (Fig. 2C). Finally, DFO is
capable of chelating other metal ions; iron repletion with iron-
bound transferrin (holo-transferrin) was used to confirm the role
of iron as well as the level necessary for normal osteoblast matu-
ration. Two concentrations of holo-transferrin, normalized with
apo-transferrin, were supplemented in the osteogenic media
with or without 5μM DFO to simulate anemic (low-TF) or physio-
logically normal (high-TF) iron concentration delivery to the cells.
As observed in Fig. 1, 5μMDFO in themedia for 21 days inhibited
Alizarin Red staining. Importantly, only high-TF in conjunction
with the 5μM DFO restored normal mineralization (Fig. 2D,E).
DFO-treated cells showed a robust induction of Tfrc, which was
reversed with high-TF treatment in 5μM DFO-treated cells at
both the day 7 and day 14 time points (Fig 2F). Examination of
osteoblast gene-expression levels showed the 5μM DFO-medi-
ated reduced levels of Bglap and Dmp1 were elevated in a
holo-transferrin dose-dependent response (Fig. 2G,H).
To investigate whether iron-deficient inhibition of osteo-
blastogenesis could be caused by the species or immortaliza-
tion of the MPC2 cells, primary human MSCs were
differentiated toward osteoblasts with the same increasing
concentrations of DFO. Similar to MPC2 cells, hMSCs exhibited
expression of the osteoblast genes SP7, COL1A1, and BGLAP
after 14 and 21 days of osteogenic differentiation (Fig. 3A–C).
Increasing concentrations of DFO showed a modest decrease
in SP7 primarily observed at day 21 with 5μM DFO compared
Fig. 3. Human mesenchymal stromal cells treated with chronic deferoxamine (DFO) show suppressed osteoblast differentiation. (A) SP7 (osterix), (B)
COL1A1, and (C) BGLAP mRNA were measured at day 14 and day 21 after osteogenic differentiation with increasing concentrations of DFO (*p < 0.05
and ****p < 0.0001 based on matched two-way ANOVA). (D) Alizarin Red staining, (E) alkaline phosphatase activity, and (F) Alizarin Red semiquantifica-
tion conducted on day 21 of osteoblast differentiation with DFO (*p < 0.05, **p < 0.01, and ***p < 0.001 from a Kruskal-Wallis test).
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with the control cells. In contrast, COL1A1 mRNA showed a
more DFO dose-dependent suppression of expression levels
at 21 days after differentiation initiation (Fig. 3B). BGLAP
mRNA levels were significantly reduced with 5μM DFO treat-
ment for both day 14 and 21 time points (Fig. 3C). Similar
to MPC2 cells, hMSCs showed reduced Alizarin Red staining
for mineralization after 21 days, with increasing DFO concen-
trations in the osteogenic media (Fig. 3D). Both alkaline phos-
phate activity and Alizarin Red staining elution showed a
DFO-dependent reduction for osteoblast activity and mineral-
ization (Fig. 3E,F).
Iron-sensing mechanisms were also examined in these cells,
including HIF1α stabilization. Protein isolated at all time points
showed accumulation of HIF1α in the DFO conditions and at all
of the time points examined (Fig. 4A). Consistent with iron defi-
ciency and hypoxia, TFRCmRNA increased in parallel with increas-
ing concentrations of DFO compared with controls (Fig. 4B). Again,
to rule out apoptosis as amechanism for decreased differentiation,
cells at 1, 3, 7, and 14 days underwent TUNEL staining (Fig. 4C).
Early time points showed no difference in apoptotic-positive cells
at any concentration of DFO. By day 14 of osteogenic differentia-
tion, a modest yet significant increase in dead cell percentage
was calculated for cells treated with 2.5 and 5μM DFO (Fig. 4D).
To evaluate the level of iron needed for proper osteoblast differen-
tiation, 5μM DFO-treated cells were additionally supplemented
with low- or high-holo-transferrin for the direct delivery of iron.
After 28 days in these conditions, Alizarin Red staining showed sig-
nificantly improvedmineralizationwith 5μMDFO cells treatedwith
high-TF; however, these did not reach control levels (Fig. 4E,F). At
the 21-day time point, the DFO-mediated induction of TFRC was
reversed in a dose-dependent manner, and the COL1A1 mRNA
levels were significantly increased also in a transferrin dose-
dependent manner (Fig. 4G,H).
Iron deficiency exhibits less severe effects
on adipogenesis
As mesenchymal progenitor cells are also capable of differentiat-
ing toward adipocytes, MPC2 cells were incubated in adipogenic
media (AM) with varying concentrations of DFO, similar to those
used in the osteogenic differentiation conditions. PPARɣ plays a
crucial role in initiating adipocyte differentiation.(35) Control AM-
treated MPC2 cells showed robust induction of Pparɣ at both
3 and 7 days after initiation. In contrast to osteogenic
Fig. 4. Human mesenchymal stromal cells (hMSCs) maintain iron-adaptive responses and cell viability during chronic iron deficiency with partial rescue
using iron supplementation. (A) HIf1αWestern blot from protein isolated 7, 14, and 21 days after initiation of osteoblast differentiation, alongwith increas-
ing concentrations of deferoxamine (DFO). (B) TFRCmRNAmeasured at 14 and 21 days of osteoblast differentiation with increasing concentrations of DFO
(*p < 0.05 and ****p < 0.0001 from matched two-way analysis of variance [ANOVA]). (C) Representative images (10; scale bar= 200μM) and (D) quan-
titation for % dead cells by enumerating TUNEL-positive (green) versus total cell (4,6-diamidino-2-phenylindole [DAPI]; blue) staining after osteogenic dif-
ferentiated for 1, 3, 7, and 14 days (**p < 0.01 using Kruskal-Wallis test). (E) hMSCs in osteogenic media were supplemented with combinations of 5μM
DFO with low concentration or high concentration of iron-bound holo-transferrin and stained for Alizarin Red after 28 days (F), which were then quanti-
fied. (G) TFRC- and (H) COL1A1 mRNA-expression levels were measured after 21 days in these conditions (**p < 0.01, ***p < 0.001, and ****p < 0.0001
based on one-way ANOVA).
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differentiation, the addition of DFO hadminimal effects on Pparɣ
expression. A total of 5μM DFO-treated cells had significantly
reduced Pparɣ mRNA levels compared with control cells after
3 days of adipogenesis. However, after 7 days of adipogenic dif-
ferentiation PparɣmRNA levels in the 5μM DFO conditions were
similar to controls (Fig. 5A). As PPARɣ regulates adipogenic dif-
ferentiation and gene expression, the factors lipoprotein lipase
(Lpl) and adiponectin (AdipoQ) mRNA expression levels were
analyzed. Lpl mRNA showed a significant reduction in the 5μM
DFO-treated cells at both the 3- and 7-day time points compared
with AM controls (Fig. 5B). AdipoQ also showed a significant reduc-
tion in the 5μM DFO-treated cells after 3 days of differentiation.
However, at day 7, AdipoQ mRNA levels were elevated above the
controls at the same time point (Fig. 5C). At the cellular level,
MPC2 cells showed lipid droplet accumulation, visualized through
Oil Red O staining, after 3 days in adipogenic media and further
increased after 7 and 14 days in the differentiation conditions
(Fig. 5D). Semiquantitation of the eluted stain showed nodifference
in lipid accumulation at the various time points with DFO supple-
mented in the adipogenic media (Fig. 5E). To further evaluate a
potential enhancement in adipogenesis, we reduced the levels of
adipogenic components to 50% of the original concentration and
repeated the MPC2 adipogenic differentiation along with DFO.
Pparγ, Lpl, and AdipoQ mRNA levels showed a dose-dependent
decrease after 3 days of differentiation, which were normalized
by day 7 (Supplementary Information Fig. S2A–C). Importantly, Oil
Red O elution after 10 days of differentiation in these conditions
also showed a dose-dependent reduction exhibiting impaired lipid
accumulation (Supplementary Information Fig. S2D).
As with osteogenic differentiation, hMSCs were also incu-
bated in AM with the same DFO concentrations. Similar to
MPC2 cells, gene expression of PPARɣ, LPL, and ADIPOQ mRNA
expression was analyzed at 1, 7, and 14 days after the initiation
of adipogenic differentiation. After 14 days, the 5μM DFO-
treated cells showed significantly reduced levels of PPARɣ, LPL,
and ADIPOQ mRNA compared with the controls, although
expression levels were substantially elevated over day 1 cells
(Fig. 6A–C). Oil Red O staining and semiquantitative elution of
the cells at day 7 and 14 time points showed no impairment in
lipid accumulation when the cells were differentiated with
increasing concentrations of DFO (Fig. 6D,E).
Discussion
Iron is a key mineral intimately involved in oxygen-sensing
mechanisms both at the cellular and systemic levels. Previous
studies have found that iron levels are correlated with BMD
and BMC,(36) and the presence of anemia increases fracture risk
independent of other known risk factors.(10) This has important
implications for other conditions known to induce anemia such
as cancer, situations of chronic inflammation, and chronic kidney
disease (CKD).(5,37,38) Indeed, iron deficiency is highly prevalent
Fig. 5. Adipocyte differentiation in MPC2 cells is not impaired with iron chelation. (A) Pparγ mRNA was analyzed at 1, 3, and 7 days after the initiation of
adipogenic differentiation with increasing deferoxamine (DFO) concentrations in parallel with (B) Lpl and (C) AdipoQmRNAs. (D) Representative images for
Oil Red O staining and lipid accumulation after 3, 7, and 14 days of adipogenic differentiation (4; scale bar = 100μM), which was then (E) eluted and
semiquantified (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 based on matched two-way analysis of variance). AM, adipogenic media.
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in patients with CKD,(37,39–41) and these patients are found to
have significantly elevated fracture risk over the general popula-
tion.(42–44) Both sequelae are independently associated with
morbidity and mortality in CKD(45–48); however, the exact role
of iron in bone homeostasis at the molecular level is unclear.
The data presented here show that iron is critical for osteoblast
differentiation and mineralization function. Addition of the iron
chelator deferoxamine throughout the differentiation of progen-
itor cells toward osteoblasts mimicked chronic iron deficiency.
Differentiation under DFO treatment ultimately blunted gene
expression of key downstream factors necessary for appropriate
differentiation. These included Col1a1, Bglap, and Dmp1 for the
mouse progenitor MPC2 cells, and SP7, COL1A1, and BGLAP in
the hMSCs. Interestingly, osterix (SP7) mRNA in the hMSCs only
displayed amodest reduction in expression levels andwas stable
in the MPC2 cells. It is possible that the mechanism of blunted
osteoblast gene expression is not caused by a change in the
upstream transcriptional factors: This requires further investiga-
tion. Ultimately, suppressed osteoblast gene expression led to
reduced mineralization as measured by Alizarin Red staining
and alkaline phosphatase activity for both cell types.
Because of the nature of the bone and bone marrow niche,
osteoblasts and their progenitors reside in regions with lower
oxygen tension compared with other parts of the body.(49) These
conditions can initiate hypoxia responses. Previous studies
examining the role of hypoxia for bone homeostasis found that
differentiating progenitor cells and osteoblasts in low oxygen
tension conditions (3%–5% O2) increased osteoblast gene
expression and mineralization compared with cells in normoxic
conditions (21% O2).
(18,50) Hypoxia-inducible factors were
deemed responsible for this effect and were modeled in vivo.
Indeed, deletion of HIF1α within the osteoblast lineage
decreased bone.(51) Alternatively, the deletion of PHDs or von
Hippel-Lindau proteins that drive HIF degradation within the
osteoblast lineage increased bone volume and density likely
because of the constitutive activation of HIF transcription fac-
tors.(52-54) Iron deficiency is also known to enhance HIF1α accu-
mulation as iron, in addition to oxygen, is a critical cofactor for
PHD activity.(55) HIF1α protein was stabilized in the hMSCs in a
DFO dose-dependent manner during osteoblast differentiation.
HIF1α stabilization was also evident after several weeks of differ-
entiation; thus, the mechanisms to adapt were not dampened in
chronic iron-deficient conditions. Despite activation of HIF1α,
however, the cells were unable to undergo osteoblastic differen-
tiation. These data suggest that iron affects pathways in osteo-
blast maturation independent of HIF1α.
Known downstream targets of hypoxia and iron-deficiency
responses include transferrin receptor, which is induced in an
effort to increase iron uptake. Indeed, transferrin receptor
expression was upregulated in a DFO dose-dependent manner
within both of the cell types in osteogenic media. This is similar
to the study by Messer et al.,(56) whereby isolated fetal rat calvar-
ial osteoblasts showed transferrin receptor induction with DFO
treatment during osteogenic differentiation. To further deter-
mine whether iron is necessary for osteoblast maturation and
function, we replenished the DFO-containing media with iron
in the form of holo-transferrin. In vitro, when osteoblasts are trea-
ted with free iron in the form of ferric ammonium citrate, this has
shown to induce cell death as free iron can be toxic to cells.(57)
Indeed, iron-overload disorders studied in mice, including
Fig. 6. Human mesenchymal stromal-cell adipocyte differentiation is unaffected by iron deficiency. (A) PPARγ, (B) LPL, and (C) ADIPOQmRNAs were ana-
lyzed at 1, 7, and 14 days of adipogenic differentiation with increasing deferoxamine concentrations. (D) Representative images for Oil Red O staining and
lipid accumulation after 7 and 14 days of adipogenic differentiation (4; scale bar = 100μM), which was then (E) eluted and semiquantified (*p < 0.05,
**p < 0.01, and ****p < 0.0001 based on match two-way analysis of variance). AM, adipogenic media.
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hereditary hemochromatosis, have been shown to have reduced
bone compared with WT mice.(58) In this way, holo-transferrin
directly delivers iron through the transferrin-receptor–mediated
pathway reducing the accumulation of free iron. Cells, differenti-
ated toward osteoblasts but not exposed to DFO, showed little
effect of holo-transferring either at the low or high concentra-
tions showing the iron-bound delivery did not result in toxicity
of the cells. Iron delivery in the control conditions modestly
reduced TfrcmRNA expression to decrease iron uptake and ulti-
mately andmodestly elevated Alizarin Red staining of these cells.
When either cell type was differentiated with 5μM DFO, holo-
transferrin restored the Tfrc/TRFC mRNA and osteoblast gene
expression in a dose-dependent manner. In MPC2 cells, the
high-TF level of iron completely rescued mineralization, whereas
hMSCs mineralization rebounded more modestly.
Using primary hMSCs and mouse progenitor cells allowed for
the assessment of iron on alternative differentiation pathways.
During aging, there is an inverse relationship between bonemar-
row adipocyte accumulation and bone strength within the verte-
brae.(29) As 5μMDFO in the osteogenic culture media was able to
significantly suppress osteoblast differentiation, we sought to
determine whether there would be a reciprocal increase in adi-
pogenesis. Concentrations of DFO, found to inhibit osteoblasto-
genesis, exhibited a very minimal effect in hMSC or MPC2 cells
cultured with adipocyte differentiation media. Indeed, iron-
deficiency conditions neither hindered nor enhanced adipogen-
esis. The expression of key adipocyte genes showed modest
reductions at the highest DFO concentration. At the cellular level,
DFO did not impair the ability of either cell type to accumulate
lipid throughout the adipogenic differentiation protocol. In fact,
the 5μM DFO-treated hMSCs were observed to have moderately
increased Oil Red O levels compared with controls. To further
evaluate the potential for iron deficiency to enhance adipogenic
differentiation we reduced the adipogenic components in the
media. We found under these conditions, iron deficiency inhib-
ited Oil Red O accumulation. This is partially in line with the study
by Mareno-Navarrete et al.(59); the authors found that DFO dra-
matically inhibited PPARɣ, ADIPOQ mRNA expression in human
preadipocytes. However, the concentrations of DFO were 4- to
20-fold higher than those used in our study. Additionally, it is
unclear how the iron contained within the media, provided by
the supplemented FBS, may have differed between the two
studies. These data suggest that when iron deficiency outweighs
adipogenic signals, adipogenesis is impaired.
Early in osteogenic differentiation, osteoblasts have high ener-
getic demands, requiring robust ATP production.(60-62) Mitochon-
dria play an essential role in this process; importantly, iron is used
as a cofactor for many enzymes within these organelles.(63) Thus,
alterations in iron could interfere with the mitochondrial biology
and cellular energy metabolism during osteoblast differentiation,
which has been implicated in other tissues.(64) The requirement
for appropriate iron concentrations for mitochondrial function
could explain our results, whereby only physiologically normal
iron concentrations supplemented media rescued mineralization
when in the presence of DFO. However, whether iron-mediated
changes in energy metabolism directly link to alterations in oste-
oblast gene expression remains to be determined. In contrast,
adipocytes have a distinct metabolic profile to that of
osteoblasts,(65) which may possibly render them less sensitive to
the effects of 5μM DFO-mediated iron depletion on mitochon-
drial dynamics. Interestingly, in mice subjected to iron deficiency,
bones display reduction in bone density yet have not exhibited
marrow fat accumulation compared with controls.(66) Therefore,
based on our in vitro culture data, this suggests that iron defi-
ciency is not sufficient to directly promote adipocyte differentia-
tion over the osteoblast pathway. In the context of dietary iron
restriction, it is possible that either the total number of progenitor
cells is reduced or there is a lack of factors within the bone mar-
row microenvironment to stimulate adipogenic differentiation.
In summary, these data suggest that osteoblasts maintain a
higher iron requirement for differentiation and function com-
pared with adipocytes, and that additional external stimuli are
needed to promote adipocyte differentiation during frank iron
deficiency. Additionally, mouse and human progenitor cells dis-
play similar phenotypes when differentiated under chronic
iron-deficiency states. By understanding the molecular alter-
ations induced by iron deficiency, this could have important
implications for helping to mitigate fracture risk in situations of
chronic low iron.
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